News

Moderna shares surged 9.5% amid legal backlash against vaccine policy changes. Will it be a turning point for MRNA which is ...
Moderna shares surged 9.5% amid legal backlash against vaccine policy changes. Will it be a turning point for MRNA which is struggling with weaker sales?
Key Takeaways The S&P 500 fell 0.1% on Tuesday, July 8, 2025, after President Trump extended the deadline for "reciprocal" tariffs and discussed a 50% levy on imported copper.Shares of Fair Isaac, ...
The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move ...
Dwight Morrow was thrilled to land a job at Moderna in June 2023 after its blockbuster Covid-19 vaccine had turned the once-obscure Cambridge biotech into a household name.
Moderna's RSV vaccine gets expanded approval for 18-59 year olds at high risk of severe illness, marking a significant step in vaccine protection.
In this photo illustration, a Moderna COVID-19 vaccine fills a syringe at Borinquen Health Care Center on May 29, 2025 in Miami, Florida.
Moderna's RSV vaccine gets expanded approval for 18-59 year olds at high risk of severe illness, marking a significant step in vaccine protection.
After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune. The coronavirus vaccine maker has seen revenue plummet as demand for ...
This is the same limited use the FDA set in licensing the Novavax COVID-19 vaccine last month. This fall, Moderna anticipates offering both Spikevax and mNexspike as COVID-19 vaccines.
The vaccine uses the same lipid nanoparticles (LNPs) as the Moderna COVID-19 vaccines. About Moderna Moderna is a leader in the creation of the field of mRNA medicine.